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Key points  
 Exposure to some AEDs during pregnancy increases the risk of major congenital 
malformations in the offspring, such as neural tube defects and cleft palate. The risk varies 
by AED with valproate having the highest risk. 
 Antiepileptic drugs (AED) should be prescribed with caution during pregnancy.  
 The study using electronic health care databases analyses AEDs prescribed to over 1 million 
pregnant women from the UK, France and Italy; 2007-16. 
 AED prescribing during pregnancy was 3.0 (2.8-3.1) per 1,000 in Emilia Romagna, 5.9 (5.6-
6.1) in Tuscany, 6.3 (5.7-6.9) in France and 7.8 (7.5-8.0) in the UK.  
 Valproate was prescribed to 28.6% of AED exposed pregnant women in Tuscany, 21.6% in 
France, 16.7% in Emilia Romagna and 11.9% in the UK.  
 Variations in AED prescribing including that of valproate during pregnancy indicate the 
potential for reductions in some regions.   
 
 
Word Count: 6099 
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Abstract  
Purpose 
To study patterns of Antiepileptic drugs (AED) prescribing, particularly valproate, during 
pregnancy over a 10 year-period in the UK, Italy and France). 
Methods 
Data on pregnancies conceived after 1st January 2007 with outcomes before 31st December 
2016 were extracted from four European electronic healthcare databases (380,499 in the 
United Kingdom (UK), 66,681 in France and 649,918 in Italy [355,767 in Emilia Romagna 
and 294,151 in Tuscany]). Prevalence of AEDs with an ATC code starting N03A and 
clobazam (N05BA09) were stratified by country and calendar year. 
Results 
AED prescribing during pregnancy varied from 3.0 (2.8-3.1) per 1,000 pregnancies in Emilia 
Romagna to 7.8 (7.5-8.0) in the UK, 5.9 (5.6-6.1) in Tuscany and 6.3 (5.7-6.9) in France. 
Lamotrigine was commonly prescribed in all regions with a third of women exposed to an 
AED during pregnancy taking lamotrigine in the UK and France. Valproate was prescribed to 
28.6% of AED exposed pregnant women in Tuscany, 21.6% in France, 16.7% in Emilia 
Romagna and 11.9% in the UK. Over the study period the prevalence of AED prescribing 
increased in the UK mainly due to increases in pregabalin and gabapentin; declined in France 
mainly related to decreases in clonazepam and remained constant in Italy. Valproate 
prescriptions declined to a prevalence <1 per 1,000 pregnancies in 2015-2016 in the UK, 
France and Emilia Romagna. 
Conclusions 
Variations in AED prescribing during pregnancy indicate the potential for further reductions, 
particularly of valproate. Increases in pregabalin/gabapentin prescribing, for which risks are 
not well-known, is a cause for concern.   
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Introduction 
Drugs classified as “Antiepileptics” in the Anatomical Therapeutic Chemical (ATC) 
classification may be indicated in several disorders depending on the country: epilepsy, bipolar 
disorder, anxiety, neuropathic pain and migraine prophylaxis. A recent European study, 
involving the United Kingdom (UK), France and Italy, showed that 1.2% to 2.9% of women 
of childbearing age received a prescription for a drug from the antiepileptic drugs (AED) ATC 
class in 20161. 
It is now well demonstrated that exposure to some AEDs during pregnancy increases the risk 
of major congenital malformations in the offspring, such as neural tube defects and cleft palate,  
from two- to three-fold2–5. The risk varies by AED6: valproate is known to have the highest 
risk2 whereas lamotrigine may represent the safest AED during pregnancy5. Furthermore, since 
the early 2000s, several studies have suggested a risk of neurodevelopmental problems in 
children exposed in-utero to valproate7 including delayed walking and talking or difficulty with 
language3,8,9. In-utero valproate exposure can also affect intelligence quotient (IQ)10, can 
increase the risk of autistic spectrum disorder11,12 and possibly the risk of attention deficit 
hyperactivity disorder (ADHD)13, although these data are more limited.  
 
In October 2014, following the warnings from the European Medicines and Healthcare 
products Regulatory Agency (MHRA) about the risks associated with the use of valproate in 
girls capable of becoming pregnant and women of childbearing potential, the European 
Medicines Agency (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) issued 
recommendations for valproate prescribing14. The recommendations included that valproate 
and related substances (valproic acid, valproate and valpromide) should not be used in girls, 
women of childbearing potential and pregnant women unless alternative treatments are 
ineffective or not tolerated; valproate and related substances should be contraindicated in 
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prophylaxis of migraine attacks in pregnancy and women of childbearing potential who are not 
using effective methods of contraception.  
These guidelines were relayed by the EMA and by Health Authorities in European countries 
such as in the UK where a guide was published for healthcare professionals in January 201515 
and in France where several letters have been sent to healthcare professionals since December 
201416,17, and in Italy by the Italian National  Medicines Agency (AIFA). Simultaneously, 
recommendations and blackbox warnings for valproate prescribing during pregnancy were 
disseminated by the Food and Drug Administration (FDA) in the United States18–20. 
 
The present descriptive drug utilisation study, capturing data from three European countries 
(UK, Italy and France), aims to study patterns of AED prescribing, particularly valproate, 
during pregnancy over a 10 year-period.  The objective consisted in providing prevalence of 
AED prescribing during pregnancy by country, by specific AEDs and by indications and also 
to describe evolution over time. 
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Methods 
Study design 
The study is a descriptive drug utilisation study, from 1 January, 2007 to 31 December, 2016.  
Data source 
Anonymous data from linked electronic healthcare databases from four regions/countries 
contributed to the study: the UK (Clinical Practice Research Datalink (CPRD), capturing a 
sample of approximately 8% of the UK population), France (Echantillon Generaliste des 
Beneficiaires (EGB): French Health Insurance System and Hospital Medical Information 
Systems (PMSI), concerning a representative  1/97 sample of the French Population), Emilia 
Romagna in Italy (Certificate of Delivery Assistance (CeDAP) and Emilia-Romagna 
Prescription Database (ERPD)) and Tuscany in Italy (CeDAP, Hospital Discharges Registry 
and Tuscany Prescription Database (TPD)). An overview of the databases has been reported in 
previous articles1,21. Ethical and data access approvals were obtained for each database from 
the relevant governance infrastructures.  
Pregnancy 
All pregnancies with a known pregnancy outcome were included. The start and end dates of 
each pregnancy in women aged between 10 and 50 years were identified within each of the 
databases during the study period using database specific algorithms. In the UK CPRD the 
algorithm incorporated all pregnancy related codes in the mother’s electronic medical record. 
In the Italian databases, the start of pregnancy was determined based on gestational age data 
and in the French database, the start of pregnancy was determined from information on 
gestational age or an algorithm incorporating other available pregnancy related data. In the UK, 
French and Tuscany databases, pregnancies that ended in a live birth, stillbirth, spontaneous 
abortion and induced termination (including those induced for non-medical reasons) were 
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identifiable. In Emilia Romagna, pregnancy data were limited to those pregnancies ending in a 
live or stillbirth. 
 
Multiple pregnancies were also included. Pregnancies were eligible for inclusion if the woman 
had been present in the study cohort for the 6 months before pregnancy and throughout the 
pregnancy.  
 
Exposure to antiepileptic drugs (AEDs) 
AEDs with an ATC classification code starting with N03A and also clobazam (N05BA09) 
were used. These drugs can be licensed, depending on the countries, for epilepsy but also for 
bipolar disorder, anxiety, migraine prophylaxis and neuropathic pain.  
AED exposure was based on the issue (UK) or the dispensing (France and Italy) of a 
prescription. Prescription duration and dose were not taken into account. Women were 
considered to be exposed to AEDs if they had received at least one prescription during the 
pregnancy. Considering the period of exposure during pregnancy, women were considered to 
be exposed during trimester 1 if they had received at least one prescription during the first 3 
months of pregnancy, in trimester 2 if they had received a prescription during months 4-6 and 
in trimester 3 if they had received a prescription from month 6 to the end of pregnancy.  
Valproate, including prescriptions for valproic acid and valpromide, was of particular interest. 
 
Indications of AED prescriptions 
Indications for prescriptions were not available, or only partially available, in the four databases 
used for this study. Consequently, each country/region developed a specific algorithm to 
determine indications for AED prescriptions, using medical information available such as 
medical diagnoses, hospital discharge data, special reimbursement status or exemption codes, 
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information on the type of prescriber, the specific name of the medicine and co-prescribing of 
other medicines. However, in Emilia Romagna and in Tuscany 31% and 49% of the indications 
could not be identified; consequently, only French and UK indication data were analysed.  
 
Statistical Methods 
Prevalence of AED prescribing were computed overall and for specific AEDs, stratified by 
country/region and calendar year at pregnancy start. The number of pregnancies in 2016 was 
low as generally only pregnancies conceived before April had outcomes before the end of the 
year. Prevalence were calculated per 1,000 pregnancies (expressed with the symbol ‰), with 
95% confidence intervals (CI95) calculated using the binomial distribution. 
Data were analyzed using STATA 15 in the UK and SAS (SAS Institute, North Carolina, USA) 
in France and Italy. 
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RESULTS 
During the study period, more than one million pregnancies were captured in the databases: 
66,681 pregnancies in France, 294,151 in Tuscany (Italy), 355,767 in Emilia Romagna (Italy) 
and 380,499 in the UK.  
 
Prevalence of AED prescribing during pregnancy 
The prevalence of AED prescribing during pregnancy varied between countries/regions from 
3.0 (2.8-3.1) per 1,000 pregnancies in Emilia Romagna to 7.8 (7.5-8.0) in the UK, with 5.9 
(5.6-6.1) in Tuscany and 6.3 (5.7-6.9) in France. 
As presented in the Table 1, lamotrigine was one of the 4 most commonly prescribed AEDs in 
all regions and the highest-prescribed AED in France and the UK. In France, 29.1% of women 
exposed to an AED during pregnancy and 33.2% in the UK were exposed to lamotrigine. 
In Tuscany, valproate was the most frequently prescribed AED during pregnancy with 28.6% 
of pregnant women exposed to an AED being prescribed it, compared to 11.9% in the UK, 
16.7% of women in Emilia Romagna, and 21.6% in France. 
Clonazepam, carbamazepine and levetiracetam were also commonly prescribed in Italy, France 
and the UK during pregnancy. For more than 10% of pregnant women exposed to an AED, 
clonazepam was prescribed in Italy (14.9% in Emilia Romagna and 13.7 in Tuscany) and 
France (18.2%). The same applied to levetiracetam in France (10.7%), Emilia Romagna 
(10.6%) and the UK (12.9). Carbamazepine was prescribed for more than 15% of pregnant 
women exposed to an AED in Emilia Romagna (22.2%), UK (16.4%) and Tuscany (15.1%). 
In France and the UK, pregabalin prescribing concerned respectively 12.6% and 13.4% of 
pregnant women exposed to an AED.  
The prevalence of AED prescribing during pregnancy increased with age in all countries, 
particularly in women over 40 years of age in France and the UK. For example, in the UK, 15.2 
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per 1,000 pregnant women aged 45 years and older received an AED during their pregnancy. 
Gabapentin and pregabalin were largely responsible for this increase. 
 
Prevalence of AED prescribing by trimesters of pregnancy (expressed per 1,000 
pregnancies as ‰) 
In all regions, there was evidence of a decline in the prevalence of women exposed to an AED 
during pregnancy when compared to the 6-month period before the start of pregnancy and also 
a decline during early pregnancy (trimester 1 and trimester 2) (Figure 1). The prevalence of 
prescribing before pregnancy was highest in the UK (8.4‰) and France (8.0‰) and lowest in 
Emilia Romagna (3.0‰). The prevalence of prescribing in Tuscany was close to France during 
pregnancy, but higher than that observed in Emilia Romagna. The UK had the highest 
prevalence of AED prescribing in all 3 trimesters. 
 
Prevalence of AED prescribing in relation to pregnancy by calendar year (expressed 
per 1,000 pregnancies as ‰) 
In the UK, the prevalence of AED prescribing increased more than 2-fold over the study period, 
with a greater increase occurring from 2012 mainly due to increases in pregabalin and 
gabapentin prescribing (Figure 2 and 3). After exclusion of pregabalin/gabapentin the 
prevalence of AED prescribing in the UK was relatively stable during the study period. In 2015, 
more than 2‰ of pregnant women received pregabalin or gabapentin prescriptions (2.3‰ and 
2.7‰ respectively), compared with less than 1‰ in 2011 (0.8‰). This trend seems to be 
confirmed in 2016. To a lesser extent, an increase in lamotrigine prescribing was identifiable, 
with the prevalence increasing from 1.8‰ in 2007 to 3.4‰ in 2015. In contrast, a decline in 
valproate prescribing was observed, from 1.4‰ in 2007 to 0.6‰ in 2015. 
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In France, there was a general decline in the prescribing of any AED during the study period 
with a prevalence of 7.4‰ in 2007 and 5.4‰ in 2015. The greatest reduction occurred between 
2008 and 2012 and was likely to be related to the large reductions in clonazepam prescribing. 
After exclusion of clonazepam, the prevalence of AED prescribing was relatively stable during 
the study period. For valproate, the prevalence of prescribing during pregnancy declined 
between 2009 and 2011 after which it has remained constant with a prevalence of 0.7‰ in 
2015 and 2016. By contrast, prevalence of lamotrigine prescribing increased during the same 
period from 1.5‰ in 2007 to 2.6‰ in 2015. 
 
In Italy, in both Emilia Romagna and Tuscany, Figure 2 shows AED prescribing was stable 
between 2007 and 2015.  However, a small decline from 0.6‰ in 2007 to 0.3‰ in 2015 in 
valproate prescribing was identified in Emilia Romagna while in Tuscany AED prescribing 
decreased from 2.0‰ in 2007 to 1.4‰ in 2015.  
 
Indications  
In the French and UK databases, 4.2‰ and 4.8‰ of pregnant women respectively received an 
AED for the treatment of epilepsy (278 out of a total of 66,681 pregnancies in France and 1,826 
out of 380,499 in the UK) (Table 2). They represent 65.9% and 61.8% respectively of the 
women exposed to AEDs during pregnancy, while 16.4% received AEDs for bipolar disorder 
in France compared with 5.4% in the UK and 11.6% for pain in France compared with 15.4% 
in the UK (including 8.6% for neuropathic pain). Other indications were less frequent, with for 
example only 2.8% and 2.4% of women who received an AED due to an anxiety disorder. 
About 9% and 12.8% of indications were not identifiable in France and the UK respectively. 
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Among women exposed to valproate during pregnancy in France, only prescriptions for bipolar 
disorder and epilepsy could be identified with 73.6% of them treated for epilepsy and 26.4% 
for bipolar disorder. In the UK, 77.1% of women exposed to valproate during pregnancy were 
treated for epilepsy, 15.9% for bipolar disorder, 4.8% with unknown indications and the 
remaining 2.2% for migraines and other psychiatric disorders.
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DISCUSSION 
Exposure to AEDs during pregnancy: differences between European countries 
More than one million pregnancies were identified in the three European countries including 
over 6,000 pregnant women who received an AED (around 6 per 1,000). The prevalence of AED 
prescribing during pregnancy varies between regions and ranges from 3 per 1,000 in Emilia 
Romagna to almost 8 per 1,000 in the UK. In the UK, the prevalence was slightly higher and in 
Emilia Romagna slightly lower than that reported by a previous EUROmediCAT study, which 
used the same databases (excluding France) but covered an earlier time period from 2004 to 
201022. The UK prevalence was also higher than that reported in another UK-based study 
between 1994 and 200923. In France, the prevalence of AED and valproate prescribing were in 
line with figures reported by recent studies using the national health insurance database linked 
to hospitalization data24. 
 
Fewer AED prescriptions in Europe than in the United States during pregnancy 
The prevalence of AED prescribing during pregnancy in all four regions was around 3 times less 
than that reported in a US-based study25where an increase in the prevalence of AED use was 
observed between 2001 and 2007, partly explained by an increase in the prescribing of 
lamotrigine and gabapentin. The US study used data from the Medication Exposure in Pregnancy 
Risk Evaluation Program (MEPREP), a collaborative program between the US Food & Drug 
Administration (FDA) and researchers from different institutions concerning around 12 million 
individuals enrolled within nine states, covering geographically and demographically diverse 
populations. 
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Heterogeneous evolution between European countries 
There was an increase over time in the prevalence of AED use during pregnancy in the UK due 
to a sharp increase in prescribing of gabapentin and pregabalin. This situation was also observed, 
to a lesser extent, for pregabalin in France, showing a new trend of AED prescribing. Concerning 
gabapentin, data in human pregnancy are insufficient to conclude whether or not there is a 
potential risk to the fetus26. Concerning pregabalin, studies in rats have shown adverse effects on 
embryo-fetal development and a signal for increased risk of major birth defects was reported27 
but not confirmed thereafter28. Moreover, pregabalin and gabapentin present a potential for abuse 
and dependence29 as mentioned in advice for prescribers disseminated in the UK, from late 
201430. Therefore, further investigations into their use and safety in pregnancy should be 
performed. 
In Italy, the prevalence of AED use during pregnancy remained stable, while in France, the 
decline in AED prescriptions over time was mainly due to the decline in clonazepam 
prescriptions linked to changes in the rules on prescribing in 2011-2012 to prevent abuse and 
misuse31. These trends were also observed in the recent study concerning women of childbearing 
potential using the same databases1. 
 
Prescription of AED mainly for the treatment of epilepsy during pregnancy  
Indications were not available in the electronic healthcare databases and algorithms to identify 
indications could only be developed successfully for France and the UK. In France 4 per 1,000 
French pregnant women were treated by AEDs for epilepsy. This is consistent with a previous 
study, carried out in another European country, which showed that around 3 in 1,000 pregnant 
women suffer from epilepsy32. The figures were similar for pregnant women in the UK. 
Over 60% of French and UK pregnant women exposed to AEDs were treated for the indication 
“epilepsy”, compared with 31% of the general population of women of childbearing potential 1. 
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This can be explained by the fact that, in Europe, it is recommended that the use of these 
medications during pregnancy must be limited to the cases where no other treatment is effective, 
a situation which occurs especially for women with epilepsy.  
In contrast, in the US, psychiatric disorders were the most prevalent diagnoses in pregnant 
women exposed to AED, followed by epilepsy and pain25.  
 
Drug choice differs according to countries    
In all regions, valproate prescriptions were issued to at least 10% of women exposed to an AED 
during pregnancy and almost 30% in Tuscany, where valproate was the most frequently 
prescribed AED throughout the entire study period. From 2007 to 2016 all regions, with the 
exception of Tuscany, observed a slight decreasing prevalence of valproate prescribing during 
pregnancy as reported in previous general population studies in Ireland and the UK33,34. 
However, since 2013 for Italy and 2014 for France and the UK several warnings around valproate 
have been published each year by National Medicines Agencies [on the AIFA (Italian Medicines 
Agency) website in Italy, on the ANSM (French Medicines Agency) website in France and on 
the MHRA (Medicines and Healthcare products Regulatory Agency) website for the UK] and 
risks associated with valproate exposure during pregnancy have been described in the scientific 
literature since the 1980s. 
 
A significant number of newborns are still exposed in utero to valproate despite the 
recommendations. It may be that the “minimal essential level” of valproate exposure in pregnant 
women has been reached (less than 1 per 1,000 pregnant women in 2015-2016 in the UK, France 
and Emilia Romagna) and that all exposures are to women where no other treatment is effective. 
However, it remains important to inform health professionals to try to further reduce exposure 
to valproate to women of childbearing age.    
16 
 
 
Lamotrigine is the most frequently-prescribed AED in France and the UK, with respectively one-
quarter and one-third of AED exposed women exposed to this AED which is in the top 4 of the 
most prescribed AEDs during pregnancy in all regions. Moreover, this drug appears to be 
increasingly used over time as observed previously in Denmark, Norway and Wales22 and 
Australia35. This situation is rather reassuring because several reviews have concluded that 
lamotrigine may be associated with a lower risk of teratogenicity36,37.  In 2009, an increased risk 
of cleft palate and lip was reported after an exposure during the first trimester of pregnancy38. 
However, this risk was not confirmed by other studies39. 
 
During the first years of the study period, carbamazepine was the most frequently prescribed-
AED in Emilia Romagna, with more than 20% of pregnant women exposed to AEDs receiving 
carbamazepine. Carbamazepine use in pregnancy is associated with an increased risk of 
malformations (RR=2.2)40, including neural tube defects, cardiovascular and urinary tract 
defects, and cleft palate41,42.  
 
Fewer AED prescriptions in pregnant women than in the general population of 
women  
 The 2 fold lower use of AEDs during the 6 months preceding the start of pregnancy may indicate 
that these pregnancies are planned. However, some women who have an AED prescription in 
early pregnancy (the most risky period for congenital anomalies) have no more prescriptions 
during the 2nd and the 3rd trimesters, suggesting that the AED treatment can be stopped or 
replaced. This emphasises the need of systematic counselling of epileptic women of childbearing 
age. 
17 
 
 
Study with some weaknesses but representative of European population 
Healthcare administrative databases allow comparison studies between countries to be 
conducted. However, some weaknesses are linked to the use of these databases1, in particular the 
absence of data on compliance with treatment and on prescriptions during hospital stays. 
Prescription duration and dose were not available and AED exposure was based solely on the 
issue or the dispensing of at least one  prescription during individually specified 3 month periods 
relating to the pregnancies. In France, AED medications are dispensed each month by the 
pharmacist, irrespective of the duration of the prescription. The patient returns to the pharmacy 
each month to get that month’s AED medication and therefore exposure during the three months 
will be reported. In Emilia Romagna (Italy), pharmacists can dispense a two-month supply of 
any medication and in the UK medications can also be dispensed for different durations, but are 
extremely unlikely to be for more than 3 months at a time. Therefore, exposure during any 
specified three month period is also likely to be captured in these databases.  
The underlying disease for which the prescription was issued was often not available in the 
databases, raising the need to develop and validate algorithms to determine indications for 
prescribing. For drugs with several indications, like AEDs, where the benefit/risk balance for 
adverse pregnancy outcomes could be different according to the maternal disease, lack of 
indication can represent a limitation for the interpretation of pregnancy medication safety studies. 
Moreover, prevalence of AED prescribing in Emilia Romagna must be considered with caution 
because pregnancy data were limited to those pregnancies ending in livebirth or stillbirth. In 
other countries, spontaneous abortions, induced terminations and unknown losses represent 
between 20 and 30% of pregnancies included in the study. Likewise, prevalence rates in 2016 
must be treated with caution since they concern only a few pregnancies (only those pregnancies 
which start in 2016 and finish in 2016). Although they represent a rich source of information, 
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administrative healthcare databases, such as those used here, were not designed to perform 
research studies. Algorithms had to be used to calculate start and end dates of the pregnancy; 
consequently, estimations of exposure periods may not be always accurate.  
 
The UK and French databases used in this study are broadly representative samples of the general 
population of these countries (around 8% of the UK population and around 1% of the French 
population). However, in Italy, dispensed prescriptions of 2 different regions only were captured 
and women included may not be representative of the general Italian population.  
  
Nevertheless, the major strength of this study is that it concerned more than one million 
pregnancies from 4 European regions allowing patterns of AED prescription during pregnancy 
to be compared in countries with different guidance on prescribing, recommendations15,17 and 
lifestyles.   
 
Future Recommendations 
During the 10 year period physicians were increasingly drawing on new drugs like pregabalin or 
gabapentin.  However, risks associated with the use of these drugs during pregnancy are not well-
known due to the lack of relevant studies. Further evaluation on their effects during pregnancy 
is needed.  Until then, healthcare practitioners should limit their prescriptions of pregabalin and 
gabapentin during pregnancy. 
Observed differences in the prevalence of AED exposure, particularly valproate, during 
pregnancy indicate that information on the risks associated with these exposures should continue 
to be further disseminated to reduce the exposure levels. Safety information should also highlight 
that valproate is contraindicated for prophylaxis of migraine headaches in pregnant women and 
in women of childbearing potential who are not using effective contraception. Valproate should 
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not be used to treat women with epilepsy or bipolar disorder who are pregnant or who plan to 
become pregnant unless other medications have failed to provide adequate symptom control and 
a pregnancy prevention plan is in place. 
 
 Conclusion 
Although the prevalence of AED prescribing during pregnancy varied between European 
countries, during the 10 year period, prescriptions for valproate during pregnancy decreased. 
However, at least 10% of pregnant women receiving an AED prescription in the study were 
prescribed valproate, hence there is further potential for reduction. At the same time, AED 
prescriptions for pregabalin and gabapentin, for which risks for the embryo or the fetus are not 
well-known, increased. Information on risks associated with exposure to valproate during 
pregnancy should continue to be widely circulated to health care providers, and studies on 
potential alternative medications should be promptly conducted. 
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Table 1 – Proportion of each specific AED prescription per 100 AED exposed women during pregnancy in each region 
 
    Emilia Romagna Tuscany France United Kingdom 
  N %   N %  N %  N %  
  Any AED 1,057a 100.0% 1,722b 100.0% 422c 100.0% 2,956d 100.0% 
Lamotrigine  N03AX09 197 18.6% 221 12.8% 123 29.1% 980 33.2% 
Any valproate   177 16.7% 492 28.6% 91 21.6% 353 11.9% 
         Valproic acid N03AG01 172 16.3% 490 28.5% 74 17.5% 353 11.9% 
         Valpromide  N03AG02 5 0.5% 2 0.1% 18 4.3% 0 -- 
Carbamazepine  N03AF01 235 22.2% 260 15.1% 31 7.3% 485 16.4% 
Pregabalin  N03AX16 61 5.8% 149 8.7% 53 12.6% 395 13.4% 
Levetiracetam  N03AX14 112 10.6% 115 6.7% 45 10.7% 382 12.9% 
Gabapentin  N03AX12 36 3.4% 102 5.9% 16 3.8% 429 14.5% 
Clonazepam N03AE01 158 14.9% 236 13.7% 77 18.2% 72 2.4% 
Topiramate  N03AX11 72 6.8% 113 6.6% 20 4.7% 183 6.2% 
Phenobarbital N03AA02 80 7.6% 174 10.1% 6 1.4% 6 0.2% 
Oxcarbazepine  N03AF02 44 4.2% 82 4.8% 10 2.4% 15 0.5% 
Clobazam N05BA09 5 0.5% 0 -- 44 10.4% 91 3.1% 
On a total of a: 355,767 pregnancies (3.0‰); b: 294,151 pregnancies (5.9‰); c: 66,681 pregnancies (6.3%); d: 380,499 pregnancies (7.8‰)
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Table 2 – Indications of AED prescriptions during pregnancy in France and United Kingdom 
 
 France United Kingdom 
  N %  N %  
Any AED 422 100.0% 2,956 100.0% 
Epilepsy 278 65.9% 1,826 61.8% 
Bipolar disorder 69 16.4% 161 5.4% 
Anxiety 12 2.8% 72 2.4% 
Pain 49 11.6% 457 15.4% 
Migraine 3 0.7% 66 2.2% 
Gen psych     57 1.9% 
Unknown 38 9.0% 377 12.8% 
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FIGURE LEGENDS 
 
Figure 1 - Prevalence of AED prescribing during each of the pregnancy trimesters and the 6 
months before the start of pregnancy by region 
Figure 2 - Prevalence of AED prescribing during pregnancy by year from 2007 to 2016 
Figure 3 - Prevalence of AED prescribing during pregnancy by country and by year from 2007 
to 2016 
 
